{"nctId":"NCT00701090","briefTitle":"A Study to Test the Safety and Efficacy of Sitagliptin Compared to Glimepiride in Patients With Type 2 Diabetes on a Stable Dose of Metformin (0431-803)(COMPLETED)","startDateStruct":{"date":"2008-05"},"conditions":["Type 2 Diabetes Mellitus, Non Insulin Dependent","Diabetes Mellitus, Non-Insulin-Dependent"],"count":1035,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: sitagliptin","Drug: open-label metformin"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Comparator: glimepiride","Drug: open-label metformin"]}],"interventions":[{"name":"sitagliptin","otherNames":["Januvia"]},{"name":"Comparator: glimepiride","otherNames":[]},{"name":"open-label metformin","otherNames":["metformin"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 18 years or older\n* Diagnosed with type 2 diabetes\n* On a stable dose of metformin of at least 1500 mg per day\n\nExclusion Criteria:\n\n* History of type 1 diabetes\n* Pregnant\n* HIV positive\n* On a weight loss program or medication\n* Has a history of blood disorder, certain cancers, heart, liver or kidney disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in HbA1c at Week 30","description":"Patient-level HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 30 HbA1c percent minus the Week 0 HbA1c percent.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.47","spread":null},{"groupId":"OG001","value":"-0.54","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in FPG (Fasting Plasma Glucose) at Week 30","description":"Change from baseline at Week 30 was defined as Week 30 minus Week 0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.6","spread":null},{"groupId":"OG001","value":"-17.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Patients With at Least One Hypoglycemia Episode of Any Type at Week 30","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":null},{"groupId":"OG001","value":"22.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight at Week 30","description":"Change from baseline at Week 30 was defined as Week 30 minus Week 0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":null},{"groupId":"OG001","value":"1.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Patients With A1C <7.0% at Week 30","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.4","spread":null},{"groupId":"OG001","value":"59.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Patients With A1C <6.5% at Week 30","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.2","spread":null},{"groupId":"OG001","value":"27.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":16,"n":516},"commonTop":["Hypoglycaemia","Nasopharyngitis"]}}}